GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sera Prognostics Inc (NAS:SERA) » Definitions » Net Margin %

SERA (Sera Prognostics) Net Margin % : -35,745.83% (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Sera Prognostics Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Sera Prognostics's Net Income for the three months ended in Dec. 2024 was $-8.58 Mil. Sera Prognostics's Revenue for the three months ended in Dec. 2024 was $0.02 Mil. Therefore, Sera Prognostics's net margin for the quarter that ended in Dec. 2024 was -35,745.83%.

The historical rank and industry rank for Sera Prognostics's Net Margin % or its related term are showing as below:

SERA' s Net Margin % Range Over the Past 10 Years
Min: -79392   Med: -42709.29   Max: -11843.79
Current: -42724.68


SERA's Net Margin % is ranked worse than
99.51% of 820 companies
in the Medical Devices & Instruments industry
Industry Median: 0.11 vs SERA: -42724.68

Sera Prognostics Net Margin % Historical Data

The historical data trend for Sera Prognostics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sera Prognostics Net Margin % Chart

Sera Prognostics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Margin %
Get a 7-Day Free Trial -79,392.00 -42,693.90 -16,487.31 -11,843.79 -42,724.68

Sera Prognostics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -19,329.27 - -34,595.83 -27,306.90 -35,745.83

Competitive Comparison of Sera Prognostics's Net Margin %

For the Medical Devices subindustry, Sera Prognostics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sera Prognostics's Net Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sera Prognostics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Sera Prognostics's Net Margin % falls into.


;
;

Sera Prognostics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Sera Prognostics's Net Margin for the fiscal year that ended in Dec. 2024 is calculated as

Net Margin=Net Income (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-32.898/0.077
=-42,724.68 %

Sera Prognostics's Net Margin for the quarter that ended in Dec. 2024 is calculated as

Net Margin=Net Income (Q: Dec. 2024 )/Revenue (Q: Dec. 2024 )
=-8.579/0.024
=-35,745.83 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sera Prognostics  (NAS:SERA) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Sera Prognostics Net Margin % Related Terms

Thank you for viewing the detailed overview of Sera Prognostics's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Sera Prognostics Business Description

Traded in Other Exchanges
N/A
Address
2749 East Parleys Way, Suite 200, Salt Lake City, UT, USA, 84109
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services.
Executives
Austin Aerts officer: Chief Financial Officer 2479 EAST PARLEYS WAY, SUITE 200, SALT LAKE CITY UT 84109
Robert Gardner Harrison officer: Chief Information Officer 320 WAKARA WAY, SALT LAKE CITY UT 84108
Zhenya Lindgardt director C/O SERA PROGNOSTICS INC, 2749 EAST PARLEYS WAY SUITE 200, SALT LAKE CITY UT 84109
John J. Boniface officer: Chief Scientific Officer C/O SERA PROGNOSTICS, INC., 2749 EAST PARLEYS WAY, SUITE 200, SALT LAKE CITY UT 84109
Mansoor Raza Mirza director C/O KARYOPHARM THERAPEUTICS INC., 2 MERCER ROAD, NATICK MA 01760
Benjamin Jackson officer: General Counsel 320 WAKARA WAY, SALT LAKE CITY UT 84108
Paul Kearney officer: Chief Data Officer 2749 E. PARLEYS WAY, C/O SERA PROGNOSTICS, INC., SALT LAKE CITY UT 84109
Joshua Phillips director C/O SERA PROGNOSTICS, INC., 2749 EAST PARLEYS WAY, SUITE 200, SALT LAKE CITY UT 84109
Jane F Barlow director 6800 BROKEN SOUND PARKWAY NW, 3RD FLOOR, BOCA RATON FL 33487
Michael R Foley officer: Chief Medical Officer C/O SERA PROGNOSTICS INC, 2749 EAST PARLEYS WAY SUITE 200, SALT LAKE CITY UT 04109
Sandra Aj Lawrence director C/O EVERGY, INC., 1200 MAIN STREET, KANSAS CITY MO 64105
Douglas Fisher officer: Chief Business Officer 587 PATROL RD, WOODSIDE CA 94062
Gregory C Critchfield director, officer: Chief Executive Officer 320 WAKARA WAY, SALT LAKE CITY UT 84108
Blue Ox Healthcare Partners Sp, Llc 10 percent owner 135 E. 57TH STREET, 23RD FLOOR, NEW YORK NY 10022
Bxhcp Sp Ii, Llc 10 percent owner 135 E 57TH STREET, 23RD FLOOR, NEW YORK NY 10022